Diabetes Metab J.  2019 Jun;43(3):379-380. 10.4093/dmj.2018.0106.

Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)

• Lee JY
• Kang ES

• KMID: 2454065
• DOI: http://doi.org/10.4093/dmj.2018.0106

Abstract

No abstract available.

MeSH Terms

Glucosides
Glycated Hemoglobin A
Sodium-Glucose Transporter 2 Inhibitors
Diabetes Mellitus, Type 2
Glomerular Filtration Rate
Glucosides
Glycated Hemoglobin A
Sodium-Glucose Transporter 2 Inhibitors

Reference

1. Lee JY, Cho Y, Lee M, Kim YJ, Lee YH, Lee BW, Cha BS, Kang ES. Predictors of the therapeutic efficacy and consideration of the best combination therapy of sodium-glucose co-transporter 2 inhibitors. Diabetes Metab J. 2019; 43:158–173.

2. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13:928–938.

3. Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015; 14:505–524.

4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128.

5. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377:644–657.